Literature DB >> 26863579

Prediction Model For Extensive Ductal Carcinoma In Situ Around Early-Stage Invasive Breast Cancer.

Floortje M Knuttel1, Bas H M van der Velden, Claudette E Loo, Sjoerd G Elias, Jelle Wesseling, Maurice A A J van den Bosch, Kenneth G A Gilhuijs.   

Abstract

OBJECTIVES: Ductal carcinoma in situ (DCIS) is a risk factor for incomplete resection of breast cancer. Especially, extensive DCIS (E-DCIS) or extensive intraductal component often results in positive resection margins. Detecting DCIS around breast cancer before treatment may therefore alter surgery. The purpose of this study was to develop a prediction model for E-DCIS around early-stage invasive breast cancer, using clinicohistopathological and dynamic contrast-enhanced magnetic resonance imaging (MRI) features.
MATERIALS AND METHODS: Dynamic contrast-enhanced MRI and local excision were performed in 322 patients with 326 ductal carcinomas. Tumors were segmented from dynamic contrast-enhanced MRI, followed by 3-dimensional extension of the margins with 10 mm. Amount of fibroglandular tissue (FGT) and enhancement features in these extended margins were automatically extracted from the MRI scans. Clinicohistopathological features were also obtained. Principal component analysis and multivariable logistic regression were used to develop a prediction model for E-DCIS. Discrimination and calibration were assessed, and bootstrapping was applied for internal validation.
RESULTS: Extensive DCIS occurred in 48 (14.7%) of 326 tumors. Incomplete resection occurred in 56.3% of these E-DCIS-positive versus 9.0% of E-DCIS-negative tumors (P < 0.001). Five components with eigenvalue exceeding 1 were identified; 2 were significantly associated with E-DCIS. The first, positively associated, component expressed early and overall enhancement in the 10-mm tissue margin surrounding the MRI-visible tumor. The second, positively associated, component expressed human epidermal growth factor receptor 2 and amount of FGT around the MRI-visible tumor. The area under the curve value was 0.79 (0.76 after bootstrapping).
CONCLUSIONS: Human epidermal growth factor receptor 2 status, early and overall enhancement in the 10-mm margin around the MRI-visible tumor, and amount of FGT in the 10 mm around the MRI-visible tumor were associated with E-DCIS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26863579     DOI: 10.1097/RLI.0000000000000255

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  4 in total

1.  Intratumoral and peritumoral radiomics based on dynamic contrast-enhanced MRI for preoperative prediction of intraductal component in invasive breast cancer.

Authors:  Hao Xu; Jieke Liu; Zhe Chen; Chunhua Wang; Yuanyuan Liu; Min Wang; Peng Zhou; Hongbing Luo; Jing Ren
Journal:  Eur Radiol       Date:  2022-01-25       Impact factor: 5.315

2.  A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis.

Authors:  Doris Leithner; Joao V Horvat; Blanca Bernard-Davila; Thomas H Helbich; R Elena Ochoa-Albiztegui; Danny F Martinez; Michelle Zhang; Sunitha B Thakur; Georg J Wengert; Anton Staudenherz; Maxine S Jochelson; Elizabeth A Morris; Pascal A T Baltzer; Paola Clauser; Panagiotis Kapetas; Katja Pinker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-13       Impact factor: 9.236

3.  Harmonization of Quantitative Parenchymal Enhancement in T1 -Weighted Breast MRI.

Authors:  Bas H M van der Velden; Michael J van Rijssel; Beatrice Lena; Marielle E P Philippens; Claudette E Loo; Max A A Ragusi; Sjoerd G Elias; Elizabeth J Sutton; Elizabeth A Morris; Lambertus W Bartels; Kenneth G A Gilhuijs
Journal:  J Magn Reson Imaging       Date:  2020-06-03       Impact factor: 4.813

4.  Characteristics and related factors of emergency department visits, readmission, and hospital transfers of inpatients under a DRG-based payment system: A nationwide cohort study.

Authors:  Pei-Fang Huang; Pei-Tseng Kung; Wen-Yu Chou; Wen-Chen Tsai
Journal:  PLoS One       Date:  2020-12-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.